New opportunities for the prevention of gastric cancer

Terapevticheskiĭ arkhiv
I G Maev, A N Kazyulin

Abstract

The approvals and provisions of the Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report and those of the Kyoto Global Consensus Conference on H. pylori-associated gastritis, concerning with the primary and secondary prevention of gastric cancer (GC), unambiguously suggest that H. pylori infection is the most important risk factor of GC. Accordingly, the basis for the primary and secondary prevention of GC is the optimization of H. pylori eradication therapy. The clear direct relationship of the risk of GC to the severity and extent of atrophic gastritis, intestinal metaplasia and dysplasia and no reversal of intestinal metaplasia and dysplasia in the presence of H. pylori eradication presume that gastroprotective agents should be used for primary and secondary prevention. Experimental and clinical findings can lead to the conclusion that rebamipide is a highly effective and safe agent for the primary and secondary prevention of GC in patients with and without H. pylori infection, by optimizing anti-Helicobacter therapy, its anti-inflammatory effect and ability to restore the cellular structure of the gastric epithelium.

References

Oct 1, 1995·Japanese Journal of Cancer Research : Gann·A M NomuraP H Chyou
Jun 1, 1996·Digestive Diseases and Sciences·N YoshidaM Kondo
Dec 17, 1997·International Journal of Cancer. Journal International Du Cancer·S MiehlkeE Bayerdörffer
May 16, 1998·Virchows Archiv : an International Journal of Pathology·A MeiningM Stolte
Sep 15, 2001·The New England Journal of Medicine·N UemuraR J Schlemper
May 7, 2002·Digestive Diseases and Sciences·K HarumaK Chayama
Aug 7, 2002·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·N KoyamaG Miyamoto
Jul 7, 2005·Postgraduate Medical Journal·M Inoue, S Tsugane
Sep 1, 2005·The American Journal of Gastroenterology·Peter MalfertheinerUNKNOWN Lejondal H. pylori-Gastric Cancer Task Force
Dec 21, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Wai K LeungJoseph J Y Sung
Feb 21, 2006·World Journal of Gastroenterology : WJG·Katherine D Crew, Alfred I Neugut
Jul 20, 2006·Journal of the National Cancer Institute·Wei-cheng YouMitchell H Gail
Dec 16, 2006·Digestive Diseases and Sciences·Tetsuya TanigawaAndrzej S Tarnawski
Dec 21, 2006·British Journal of Cancer·F KamangarS M Dawsey
Jul 5, 2007·The American Journal of Gastroenterology·William D CheyUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Feb 23, 2008·Cancer Causes & Control : CCC·Ricardo Ladeiras-LopesNuno Lunet
Sep 13, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Nao KinjoYoshihiko Maehara
Jul 22, 2009·Annals of Internal Medicine·Lorenzo FuccioFranco Bazzoli
Oct 31, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·V Herrera, J Parsonnet
Mar 23, 2010·Helicobacter·Masahiro AsakaUNKNOWN Japanese Society for Helicobacter Research
Apr 16, 2010·Digestive Diseases and Sciences·Lisette G CapelleErnst J Kuipers
Oct 19, 2010·Gastroenterology Clinics of North America·Takahisa Furuta, David Y Graham
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Apr 12, 2012·Gut·Peter MalfertheinerUNKNOWN European Helicobacter Study Group

❮ Previous
Next ❯

Citations

May 2, 2020·International Journal of Molecular Sciences·Maria Manuel AzevedoFátima Baltazar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.